Mark Goldstein
Hematology & Oncology · van Nuys, CANPI 1487758033
Payments from drug & device makers
What this record shows
Almost everything reported here is food and beverage — 97.3% of the total across 227 separate payments, which is the pattern of a clinician who attends manufacturer presentations rather than one with a consulting arrangement. It is spread thinly across 40 manufacturers, the largest accounting for just 13.9% — the pattern of someone who eats at a lot of different presentations. Reporting peaked in 2019 at $4,176 and has fallen 99.7% since, to $14 in 2023.
Across 227 payments — averaging $21.14 each. Meals, travel, consulting and speaking fees, gifts and royalties reported by drug and device makers.
- AstraZeneca$668
- Genentech USA, Inc.$351
- E.r. Squibb & Sons, L.L.C.$337
- Merck$240
- Sanofi$236
- Taiho Oncology, Inc.$213
- plus $3K from 34 others
What the payments were for
- Food & beverage$4,67097%
- Education$1273%
Most of this is food and beverage — typically meals provided during product presentations at a clinic or hospital. Nationally that is the single largest category of reported payments by count.
General payments by program year
Who reported the general payments
Companies are grouped under their corporate parent — a single manufacturer often files under several CMS reporting entities. Research and ownership payments are counted separately and are not in this table.
| Company | Payments | Total |
|---|---|---|
| AstraZeneca(2 entities) | 28 | $668 |
| Genentech USA, Inc. | 20 | $351 |
| E.r. Squibb & Sons, L.L.C. | 20 | $337 |
| Merck | 13 | $240 |
| Sanofi | 13 | $236 |
| Taiho Oncology, Inc. | 4 | $213 |
| Seagen Inc. | 10 | $207 |
| Novartis | 10 | $202 |
| Bristol Myers Squibb | 8 | $186 |
| Incyte Corporation | 11 | $177 |
| Amgen | 6 | $175 |
| Takeda Pharmaceuticals U.S.A., Inc. | 6 | $142 |
| Puma Biotechnology, Inc. | 6 | $139 |
| Lilly USA, LLC | 7 | $135 |
| Johnson & Johnson(2 entities) | 6 | $121 |
| Rigel Pharmaceuticals, Inc. | 5 | $105 |
| Tesaro, Inc. | 4 | $103 |
| Pfizer | 7 | $100 |
| Boehringer Ingelheim | 5 | $96 |
| Teva Pharmaceuticals USA, Inc. | 5 | $91 |
| Aurobindo Pharma USA, Inc. | 1 | $87 |
| Bayer | 4 | $84 |
| EMD Serono, Inc. | 3 | $68 |
| Clovis Oncology, Inc. | 3 | $68 |
| Daiichi Sankyo Inc. | 3 | $63 |
| Mylan Institutional Inc. | 2 | $47 |
| Eisai Inc. | 2 | $46 |
| Pharmacyclics LLC, An Abbvie Company | 2 | $46 |
| Jazz Pharmaceuticals Inc. | 2 | $44 |
| Karyopharm Therapeutics Inc. | 1 | $33 |
| Regeneron Healthcare Solutions, Inc. | 1 | $25 |
| Tersera Therapeutics LLC | 1 | $24 |
| Astellas Pharma US Inc | 1 | $24 |
| Array Biopharma Inc | 1 | $22 |
| Novocure Inc. | 1 | $22 |
| Lexicon Pharmaceuticals, Inc. | 1 | $18 |
| Exelixis Inc. | 1 | $17 |
| Secura Bio, Inc. | 1 | $17 |
| Beigene USA, Inc. | 1 | $14 |
| Sanofi-aventis U.S. LLC | 1 | $1 |
What the payments were tied to
Products named in the reported payments. Only payments of $100 or more are attributed here — the typical reported payment nationally is a meal worth about $16, and listing those product-by-product would be noise.
- Lonsurf$155
How this compares
$4,798 in reported general payments places this provider in the 55th percentile of 1,363 hematology & oncology providers in California.
Other hematology & oncology in van Nuys
- Dennis SlamonLos Angeles$3.1M
- Sandra HorningStanford$2.5M
- Mohammadbagher ZiariCorona$2.5M
- George YaghmourLos Angeles$1.9M
- Robert VescioWest Hollywood$1.1M
- Kevin KellyLos Angeles$894K
- Johnny ChangEncino$884K
- Nitin RohatgiSacramento$814K
- Omid HamidSanta Monica$809K
- Catherine CoombsOrange$786K
Where these figures come from
- Payments: CMS Open Payments, program years 2019–2025 (publication P06302026_06032026).
- Identity: NPPES NPI Registry, July 2026.